At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...
The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...
Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...
Hosted on MSN5m
Denmark's Novo Nordisk Rebounds Pre-Market On UBS Upgrade, But Trump's Tariff Threats Over Greenland Leaves Retail UneasyNovo Nordisk shares climbed over 3% in Wednesday's pre-market trading as U.S. stock futures rebounded from a tech-driven ...
Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a study ...
Drugs for metabolic diseases, vaccines and cancer therapies feature among new product launches this year that could top $1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback